Dr Martin Forster, Consultant Medical Oncologist

Dr Martin Forster

Consultant Medical Oncologist

Book online
|

Dr Martin Forster MBBS, FRCP, PhD

Consultant Medical Oncologist

MBBS, FRCP, PhD

Dr Martin Forster

Consultant Medical Oncologist MBBS, FRCP, PhD

Book online
|
MBBS, FRCP, PhD
HCA-Healthcare-UK

Areas of expertise

  • Medical oncology
  • Lung cancer
  • Head and neck cancer
  • Thoracic cancer
  • Chemotherapy
HCA-Healthcare-UK

Recommendations for Dr Forster

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byDr Diana Maria Davenport, GP

    Keen researcher in novel treatment and also has good patient rapport

  • byDr Diana Maria Davenport, GP

    Keen researcher in novel treatment and also has good patient rapport

  • Address

    • HCA UK at University College Hospital

      Grafton Way Building, 1 Grafton Way, London, WC1E 6AG

    • LOC - Leaders in Oncology Care

      95-97 Harley Street, London, W1G 6AF

    • The Harley Street Clinic

      35 Weymouth Street, London, W1G 8BJ

    About Dr Martin Forster

    GMC number: 4129392

    Year qualified: 1994

    Place of primary qualification: University of Newcastle upon Tyne

    Dr Martin Smith is a distinguished consultant in medical oncology at University College Hospital (UCH) and a clinical senior lecturer at University College London (UCL). He specialises in the treatment and management of lung and head and neck cancers. Dr Smith graduated from the University of Newcastle upon Tyne and gained extensive general medical experience in New Zealand, Australia, and the United Kingdom. He became a member of the Royal College of Physicians (UK) in 2000.

    Dr Smith has dedicated his career to cancer care, training in medical oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. He earned a PhD from the Institute for Cancer Research in London and was honoured with the EORTC-PAMM Young Investigator Award in 2004. Completing his specialist training in medical oncology in 2008, he was appointed as a UCL clinical senior lecturer and UCH consultant in medical oncology in 2009.

    Since his appointment, Dr Smith has been at the forefront of cancer research, running a research-based practice and serving as principal or chief investigator for over 20 early and late-phase clinical trials. His research interests focus on drug development and leveraging the growing understanding of cancer biology to design studies that identify patient populations most likely to benefit from new drugs and drug combinations.

    Dr Smith is deeply involved in the management of patients with lung and head and neck cancers. His expertise includes chemotherapy, drug development, and cancer biology. He is particularly interested in the biological mechanisms that lead to the development of these cancers, aiming to improve patient outcomes through innovative treatment strategies.

    Dr Smith's commitment to advancing cancer treatment and his extensive experience in clinical trials make him a leading figure in the field of medical oncology.

    Areas of expertise

    • Thoracic oncology
    • Head oncology
    • Neck oncology

    Professional memberships

    Royal College of Physicians
    General Medical Council

    Articles by Dr Martin Forster

    Study protocol for the saron trial: a multicentre, randomised controlled phase trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer

    Fc-optimized anti-cd25 depletes tumor-infiltrating regulatory t cells and synergizes with pd-1 blockade to eradicate established tumors

    Antitumor activity of lurbinectedin (pm01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase i study

    Phase 1/2a trial of intravenous bal101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

    Guidance by molecular selection improves the outcome of early phase treatment for gynecological (gyn) cancers

    Allele-specific hla loss and immune escape in lung cancer evolution

    Tracking the evolution of non–small-cell lung cancer